Written question asked by Wendy Chamberlain (Liberal Democrat) on Monday, 8 December 2025, in the House of Commons. It was due for an answer on Wednesday, 10 December 2025. It was answered by Zubir Ahmed (Labour) on Monday, 15 December 2025 on behalf of the Department of Health and Social Care.
Vorasidenib
- Question
-
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of the use of the drug Vorasidenib to manage the symptoms and progression of low grade Glioma.
- Answer
-
While the Department has made no assessment, the National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS on the basis of an assessment of clinical and cost effectiveness. NICE is currently evaluating vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years old and over.
The draft guidance was shared with all stakeholders as well as being published on the NICE website for public comment as part of the consultation which took place between 15 October and 4 November 2025. The committee reviewed the consultation comments at the committee meeting on 20 November 2025. NICE currently expect to publish final guidance in January 2026.
Secondary information
- Type
- Written question
- Reference
- 97926
- Session
- 2024-26
- Subjects
- Medical treatments Brain Tumours Vorasidenib
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2025-12-15 10:22:31 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/97926
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/97926
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/97926